Study type: In vivo/preclinical · Status: Verified against declared source

Humanin Treatment Protects Against Venetoclax-Induced Bone Growth Retardation inCultured Rat Bones.

Journal of the Endocrine Society · 2024

Study scale: Immunohistochemistry was performed as previously described [30].

Product or molecular entity relationships

Humanin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Growth plate biopsies were collected from the proximal femur and distal tibia in 1 constitutionally tall 13-year-old mid-pubertal male patient undergoing epiphysiodesis surgery aiming to reduce his further growth.

Methods

Despite the progress in the efforts being undertaken for rigorous investigation and early identification of treatment-induced skeletal toxicities in childhood cancer, the available therapeutic or preventive strategies to protect bone tissue remain scarce.

Scale or participants

Immunohistochemistry was performed as previously described [30].

Key findings

Recent preclinical studies reported that the BCL-2 inhibitor venetoclax can impair bone growth.

Limitations and uncertainty

Venetoclax suppressed metatarsal bone growth and when combined with HNG, bone growth was rescued and all histological parameters affected by venetoclax monotherapy were normalized.

Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.